China channel feed – Endpoints News

China channel feed

This Chinese pharma filed for an IPO last September. Seven months and a $283M investment later, they are back at the HKEX

7 years ago

Chinese player joins a growing group of biotechs buying into Synaffix's ADC linker tech

7 years ago

Vas Narasimhan has high hopes for Novartis' China drive as a blockbuster drug gets a nod

7 years ago

Eight months after filing for IPO, the maker of China's Ebola vaccine joins HKEX with $161M raise

7 years ago

Shanghai-based cancer drugmaker Abbisko lines up $42M B round as it makes a leap for the clinic

7 years ago

Oncology dominates a 'Cambrian explosion' in China's drug pipeline as McKinsey guru bets on a burst of innovation

7 years ago

Backed by OrbiMed, Lilly and now Advantech, China's InventisBio loads up $70M to propel cancer, metabolic pipeline

7 years ago

Abpro bags $60M in near-term R&D cash in tie-up with China's NJCTTQ, with eyes on bispecific T cell engagers

7 years ago

In HKEX's first test in 2019, CStone seeks up to $304M in IPO fortune

7 years ago

Hillhouse Capital endorses China-based HaiHe Biopharma's cancer pipeline in $146M round

7 years ago

Zai Lab nabs speedy China regulatory review for PARP drug Zejula

7 years ago

Mass cloning for neuro research? Chinese scientists report birth of five gene-edited monkeys

7 years ago

Chinese government probe condemns Jiankui He as rogue scientist pursuing 'illegal' work on gene-edited babies

7 years ago

In a first, China’s BeiGene scores FDA ‘breakthrough’ status for BTK inhibitor — potential rival for Imbruvica

7 years ago

Ramping up in-house drug development, API maker BrightGene bags $80M round led by Sequoia China

7 years ago

Prepping a cross-Pacific move, OrbiMed-backed Apollomics bags $100M Series B for I/O combos

7 years ago

With early-stage studies underway, Connect Biopharmaceuticals closes $55M round to advance immune modulators

7 years ago

China greenlights second homegrown PD-1 in 10 days as Innovent celebrates its first drug OK with Eli Lilly

7 years ago

What other biotech news have you been missing? A big China IPO and more

7 years ago

FibroGen, AstraZeneca score China approval for anemia drug ahead of pivotal US data

7 years ago

Junshi wins the race for first made-in-China PD-1 approval as execs reap $394M IPO harvest

7 years ago

Broadening its oncology focus, Innovent adds three Incyte drugs to portfolio for $40M cash

7 years ago

WuXi AppTec cruises toward a steady debut in Hong Kong stock exchange, ending flat on IPO price

7 years ago

Joining hunt for hep B cure, Brii Bio inks maiden deals featuring VBI, Vir, WuXi with a big appetite for more

7 years ago

First page Previous page 21 22 232425 26 27 Next page Last page